Clinical

The FDA has issued a warning for Viberzi that patients who do not have a gallbladder have an increased risk of developing serious pancreatitis.

A preview of some of the discussions at the 22nd Annual Conference of the National Comprehensive Cancer Network (NCCN).

The National Organization for Rare Disorders (NORD) has come out strongly against a bill that would provide employers with insight into workers’ personal medical and genetic information.

This week, the top managed care stories included the Congressional Budget Office releasing its rating of the GOP's health plan, the Senate voted to confirm Seema Verma for CMS administrator, and Scott Gottlieb, MD, was nominated to lead the FDA.

The White House budget “blueprint” for 2018, which was released today, has recommended substantial cuts to the National Institutes of Health (NIH).

Pembrolizumab (Keytruda) received an accelerated approval for adult and pediatric patients with refractory classical Hodgkin lymphoma or those who have relapsed after at least 3 lines of therapy.

Ken Tarkoff, formerly at RelayHealth, is joining Syapse as its new CEO.

New research published in Nature Medicine has identified a broader population of individuals with breast cancer who can have therapeutic sensitivity to PARP inhibitors.

A new study, published in the Journal of the National Cancer Institute, has confirmed that mammographic density change following estrogen and progestin treatment increases the risk of breast cancer.

The selective BCR-ABL1 kinase inhibitor imatinib mesylate (Gleevec) has been found to be safe and effective following almost 11 years of follow-up in patients with chronic myeloid leukemia.

A study evaluating patients diagnosed with thyroid cancer who refused a clinical intervention for fear of being overdiagnosed has reported that the individuals feel isolated and anxious.

The main focus of Humana’s business activities is to provide a better experience for patients and physicians, according to Roy Beveridge, MD, chief medical officer of Humana. This patient-centered approach is informed by his work as a practicing oncologist, where he learned to think about clinical programs from the perspective of the patient.

A new study from the MD Anderson Cancer Center has identified factors that influence cancer clinical trial accrual rates.

A pilot study conducted at a safety net hospital has armed researchers with a new educational tool: a digital app to persuade parents to vaccinate their adolescent against the human papilloma virus (HPV).

First-line pembrolizumab every 3 weeks followed by second-line ipilimumab, and first-line nivolumab followed by second-line ipilimumab are cost-effective strategies in patients with advanced melanoma expressing wild-type BRAF.

Pharmacists and pharmacy technicians working at 50 specialty pharmacy locations owned by Walgreens have completed a cancer-focused curriculum of advanced education courses.

The widespread nature of the opioid epidemic will require coordination from a variety of stakeholders and all levels of government. In this podcast, experts discuss how the crisis got so out of hand, various tactics being undertaken to reverse the opioid, and the current impact of stigma on getting treatment.

How will drug developers price gene therapy treatments to recover their investment and ensure that society can bear the impending cost?

Implementation of clinical pathways saved $15,013 in the total cost of care per patient over a year.

While colorectal cancer screening rates have seen a recent progress toward achieving the Healthy People 2020 objectives, breast cancer screening rates have remained static, and cervical cancer screening rates have been declining.

The company did not recover from the 5 patient deaths associated with JCAR015 in 2016.

By the time the opioid epidemic was dominating headlines, it was already out of control. So how did the epidemic sneak up on the United States, and what is being done at the state and federal levels to combat the issue?